Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference
August 04 2009 - 6:00AM
PR Newswire (US)
CARLSBAD, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense
therapeutics, today announced that management will present a
company overview at the 29th Annual Canaccord Adams Global Growth
Conference on Tuesday, August 11, 2009, at 1:00 p.m. ET at the
Boston InterContinental Hotel. A live audio webcast of the
presentation will be available on the "Investors & Media"
section of the Company's Web site, http://www.isispharm.com/. A
replay of the presentation will be available on the Isis Web site
within 48 hours and will be archived for a limited time. About Isis
Pharmaceuticals, Inc. Isis is exploiting its expertise in RNA to
discover and develop novel drugs for its product pipeline and for
its partners. The Company has successfully commercialized the
world's first antisense drug and has 19 drugs in development. Isis'
drug development programs are focused on treating cardiovascular,
metabolic and severe neurodegenerative diseases and cancer. Isis'
partners are developing antisense drugs invented by Isis to treat a
wide variety of diseases. Isis and Alnylam Pharmaceuticals are
joint owners of Regulus Therapeutics Inc., a company focused on the
discovery, development and commercialization of microRNA
therapeutics. Isis also has made significant innovations beyond
human therapeutics resulting in products that other companies,
including Abbott, are commercializing. As an innovator in RNA-based
drug discovery and development, Isis is the owner or exclusive
licensee of over 1,600 issued patents worldwide. Additional
information about Isis is available at http://www.isispharm.com/.
DATASOURCE: Isis Pharmaceuticals, Inc. CONTACT: Kristina Lemonidis,
Director, Corporate Communications, +1-760-603-2490, or Amy
Blackley, Ph.D., Assistant Director, Corporate Communications,
+1-760-603-2772, both of Isis Pharmaceuticals Web Site:
http://www.isispharm.com/
Copyright